Researchers Publish Review Outlining Thioredoxin System as a Therapeutic Target in Cellular Senescence and Ageing

A literature review published in Ageing Research Reviews identifies the mammalian thioredoxin system as a key molecular link between redox homeostasis and cellular senescence, indicating its potential as a geroscience target despite limited direct evidence in aged mammals.

A systematic literature review published in Ageing Research Reviews has evaluated the mammalian thioredoxin system's role in cellular senescence and ageing biology.

The paper, authored by researchers from Jilin University and the National University of Singapore, synthesized data from PubMed, Web of Science, and Scopus up to July 2026.

The researchers analyzed the distinct, context-dependent roles of cytosolic Trx-1, mitochondrial Trx-2, thioredoxin reductases (TrxR1, TrxR2), and the inhibitor TXNIP in senescence initiation, maintenance, and associated tissue dysfunction.

Cellular senescence contributes directly to age-related decline through cell-cycle arrest, DNA damage, mitochondrial dysfunction, and the secretion of pro-inflammatory SASP factors.

Redox imbalance is a primary driver in the initiation and maintenance of cellular senescence, making the regulatory components of the thioredoxin system logical therapeutic targets.

The review highlights multiple therapeutic avenues, including isoform-selective inhibitors, redox modulators, and senomorphic approaches, establishing a theoretical framework for future geroscience drug development.

The publication establishes the thioredoxin system as an emerging candidate target for geroscience, potentially diversifying the range of therapeutic mechanisms explored by longevity biotechnology companies.

However, because the authors explicitly note that direct evidence of these therapeutic approaches in aged mammals remains limited, immediate commercial translation is unlikely, and any related corporate development programs remain in the highly speculative, preclinical phase.

The publication of primary experimental studies in aged mammalian models to provide the direct in vivo validation required before these targets can transition into clinical-stage development.